PM060184, which is a marine-derived, synthetically-produced compound, had demonstrated strong in vitro and in vivo antitumour activity and a favourable safety profile in preclinical toxicology studies.
The trials will be conducted in the US, France and Spain.
The primary endpoints of the trial will be to identify the dose limiting toxicity (DLT), the maximum tolerated dose (MTD) and the recommended dose (RD) of PM060184.
In addition, the drug’s pharmacokinetic profile will be defined and a preliminary evaluation of its antitumour activity in patients will be performed.